CSL (OTCMKTS:CSLLY) Shares Gap Down – Time to Sell?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) shares gapped down prior to trading on Wednesday . The stock had previously closed at $31.91, but opened at $30.50. CSL shares last traded at $31.6550, with a volume of 802 shares.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Royal Bank Of Canada raised CSL from a “hold” rating to a “moderate buy” rating in a research report on Tuesday, September 15th. Jefferies Financial Group downgraded CSL from a “strong-buy” rating to a “hold” rating in a report on Friday, May 29th. Finally, Zacks Research upgraded CSL from a “strong sell” rating to a “hold” rating in a report on Friday, August 7th. One research analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, CSL currently has a consensus rating of “Hold”.

CSL Stock Performance

The stock’s 50-day moving average is $26.79 and its two-hundred day moving average is $23.33. The company has a current ratio of 2.21, a quick ratio of 0.97 and a debt-to-equity ratio of 0.60.

CSL Company Profile

CSL Limited (OTCMKTS:CSLLY) is an Australian biotechnology company that develops, manufactures and supplies medicines and vaccines. Founded in 1916 as the Commonwealth Serum Laboratories, the company was privatized in 1994 and has grown into a global provider of specialized biopharmaceutical products.

CSL’s principal businesses include CSL Behring, which develops plasma-derived and recombinant therapies for immune deficiencies, bleeding disorders and other serious medical conditions; CSL Seqirus, which produces influenza and other vaccines; and CSL Vifor, which focuses on therapies for iron deficiency, kidney disease and related conditions.